Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas

Sharma, 2009, A proposed clinical staging system for obesity, Int J Obes (Lond), 33, 289, 10.1038/ijo.2009.2 Bray, 2004, Medical consequences of obesity, J Clin Endocrinol Metab, 89, 2583, 10.1210/jc.2004-0535 Guo, 2014, The progression of cardiometabolic disease validation of a new cardiometabolic disease staging system applicable to obesity, Obesity (Silver Spring), 22, 110, 10.1002/oby.20585 Kramer, 2013, Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis, Ann Intern Med, 159, 758, 10.7326/0003-4819-159-11-201312030-00008 Centro de prensa de la Organización Mundial de la Salud. Obesidad y sobrepeso [consultado 10 Feb 2018]. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/ Cefalu, 2015, Advances in the science treatment and prevention of the disease of obesity: Reflections from diabetes care editors’ expert forum, Diabetes Care, 38, 1567, 10.2337/dc15-1081 Wing, 2013, Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes, N Eng J Med, 369, 145, 10.1056/NEJMoa1212914 Deneschvar, 2016, FDA-approved anti-obesity drugs in the United States, Am J Med, 129 Sjöstrom, 2004, Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery, N Eng J Med, 351, 2683, 10.1056/NEJMoa035622 Arterburn, 2015, Association between bariatric surgery long term survival, JAMA, 313, 62, 10.1001/jama.2014.16968 Purnell, 2016, Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: Results of the longitudinal assesment of bariatric surgery study, Diabetes Care, 39, 1101, 10.2337/dc15-2138 Mingrone, 2015, Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an Open-label, single-centre, randomised controlled trial, Lancet, 386, 964, 10.1016/S0140-6736(15)00075-6 Schauer, 2017, Bariatric surgery versus intensive medical therapy for diabetes -5- year outcomes, N Engl J Med, 376, 641, 10.1056/NEJMoa1600869 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 2012, Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study, Diabetes Care, 35, 731, 10.2337/dc11-1299 Adeyemo, 2015, Effects of metformin on energy intake and satiety in obese children, Diabetes Obes Metab, 17, 363, 10.1111/dom.12426 Ferrannini, 2015, Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition, Diabetes Care, 38, 5, 10.2337/dc15-0355 Vasilakou, 2013, Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and metanalysis, Ann Intern Med, 159, 262, 10.7326/0003-4819-159-4-201308200-00007 Johnston, 2017, Canaglifozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: Systematic review and economic evaluation, Health Technol Assess, 21, 1, 10.3310/hta21020 Zinman, 2015, Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes, N Eng J Med, 373, 2117, 10.1056/NEJMoa1504720 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Eng J Med, 377, 644, 10.1056/NEJMoa1611925 Courtney, 2017, Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists, Diabetes Metab Syndr Obes, 10, 79, 10.2147/DMSO.S126763 Røder, 2018, Major adverse cardiovascular event reduction with GLP1 and SGLT2 agents: Evidence and clinical potencial, Ther Adv Chronic Dis, 9, 33, 10.1177/2040622317735283 DeFronzo, 2017, Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor, Diabetes Obes Metab, 19, 1353, 10.1111/dom.12982 Lee, 2017, Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, Ann Pediatr Endocrinol Metab, 22, 15, 10.6065/apem.2017.22.1.15 Htike, 2017, Efficacy and safety on glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis, Diabetes Obes Metab, 19, 524, 10.1111/dom.12849 Ahmann, 2018, Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label randomized clinical trial, Diabetes Care, 41, 258, 10.2337/dc17-0417 Yandrapalli, 2017, Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus, J Thorac Dis, 9, 2124, 10.21037/jtd.2017.06.70 Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Eng J Med, 375, 311, 10.1056/NEJMoa1603827 Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Eng J Med, 375, 1834, 10.1056/NEJMoa1607141 Portillo-Sánchez, 2016, Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus, Clin Diabetes Endocrinol, 2, 9, 10.1186/s40842-016-0027-7 Frias, 2016, Lancet Diabetes Endocrinol, 4, 1004, 10.1016/S2213-8587(16)30267-4 Ludvik, 2018, Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 10.1016/S2213-8587(18)30023-8 Fulcher, 2016, Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes, Diabetes Obes Metab, 18, 82, 10.1111/dom.12589 Bray, 2016, Management of obesity, Lancet, 387, 1947, 10.1016/S0140-6736(16)00271-3 Jensen, 2014, 2013 AHA/ACC/TOS guideline for management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, J Am Coll Cardiol, 63, 2895 Aldekhail, 2015, Effect of orlistat on glycemic control in overweight and obese patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials, Obes Rev, 16, 1071, 10.1111/obr.12318 Torgerson, 2004, XENical in the prevention of diabetes in obeses subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Zanella, 2006, Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: The ARCOS study, Arq Bras Endocrinol Metabol, 50, 368, 10.1590/S0004-27302006000200023 Saunders, 2018, Obesity pharmacotherapy, Med Clin North Am, 102, 135, 10.1016/j.mcna.2017.08.010 O’Neil, 2012, Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study, Obesity (Silver Spring), 20, 1426, 10.1038/oby.2012.66 Pi-Sunyer, 2016, Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: Analysis of week 52 responders and nonresponders, Postgrad Med, 128, 591, 10.1080/00325481.2016.1208618 Fujioka, 2015, Current and emerging medications for overweight or obesity in people with comorbidities, Diabetes, Obes and Metab, 17, 1021, 10.1111/dom.12502 Neff, 2017, Network meta-anlysis of loracserine and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity, Clin Obes, 7, 337, 10.1111/cob.12213 Davies, 2015, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial, JAMA, 314, 687, 10.1001/jama.2015.9676 Le Roux, 2017, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management individuals with prediabetes: A randomised, double-blind trial, Lancet, 389, 1399, 10.1016/S0140-6736(17)30069-7 Aronne, 2013, Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults, Obesity (Silver Spring), 21, 2163, 10.1002/oby.20584 Munro, 1968, Comparison of continuous and intermittent anorectic therapy in obesity, Br Med J, 1, 352, 10.1136/bmj.1.5588.352 Gadde, 2011, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial, Lancet, 377, 1341, 10.1016/S0140-6736(11)60205-5 Garvey, 2014, Weight-loss therapy in type 2 diabetes: Effects of phentermine and topiramate extended release, Diabetes Care, 37, 3309, 10.2337/dc14-0930 Garvey, 2014, Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release, Diabetes Care, 37, 912, 10.2337/dc13-1518 Hollander, 2013, Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes, Diabetes Care, 36, 4022, 10.2337/dc13-0234 Smith, 2017, Coadministration of lorcaserin and phentermine of weight management: A 12-week, randomized, pilot safety study, Obesity (Silver Spring), 25, 857, 10.1002/oby.21811 Hollander, 2017, Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals with out diabetes: A randomized clinical trial, Diabetes Care, 40, 632, 10.2337/dc16-2427 Wilding, 2018, Medication use for the treatment of diabetes in obese individuals, Diabetologia, 61, 265, 10.1007/s00125-017-4288-1 Le Roux, 2018, Bariatric surgery for obesity, Med Clin North Am, 102, 165, 10.1016/j.mcna.2017.08.011 Cummings, 2018, Metabolic surgery for treatment of type 2 diabetes in obese individuals, Diabetologia, 61, 257, 10.1007/s00125-017-4513-y Buchwald, 2004, Bariatric surgery: A systematic review and meta-analysis, JAMA, 292, 1724, 10.1001/jama.292.14.1724 Rubino, 2016, Metabolic surgery in the treatment algorithm for type 2 diabetes: A Joint Statement by International Diabetes Organizations, Diabetes Care, 39, 861, 10.2337/dc16-0236 Simonson, 2018, Clinical and patient-centered outcomes in obese type 2 diabetes patients 3 years after randomization to roux-en Y gastric bypass surgery versus intensive lifestyle management: The SLIMM-T2D study, Diabetes Care, 41, 670, 10.2337/dc17-0487 Lecube, 2016, Trends in bariatric surgery in spain in the twenty-first century: Baseline results and 1-month follow up of the RICIBA, a national registry, Obes Surg, 26, 1836, 10.1007/s11695-015-2001-3 Rubino, 2004, The early effect of the Roux-en- Y gastric bypass on hormones involved in body weight regulation and glucose metabolism, Ann Surg, 240, 236, 10.1097/01.sla.0000133117.12646.48 Basso, 2011, First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1 and PYY changes 72h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis, Surg Endosc, 25, 3540, 10.1007/s00464-011-1755-5 Batterham, 2016, Mechanisms of diabetes improvement following bariatric/metabolic surgery, Diabetes Care, 39, 893, 10.2337/dc16-0145 Cummings, 2005, 2004 ABS Consensus Conference Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery, Sur Obes Relat Dis, 1, 358, 10.1016/j.soard.2005.03.208 Rubino, 2006, The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of proximal small intestine in the pathophysiology of type 2 diabetes, Ann Surg, 244, 741, 10.1097/01.sla.0000224726.61448.1b Anhe, 2017, The gut microbiota as a mediator of metabolic benefits after bariatric surgery, Can J Diabetes, 41, 439, 10.1016/j.jcjd.2017.02.002 Cummings, 2016, Bariatric/metabolic surgery to treat type 2 diabetes in patients with BMI <35kg/m2, Diabetes Care, 39, 924, 10.2337/dc16-0350 2018, American Diabetes Association. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes—2018, Diabetes Care., 41, S65 Mechanick, 2013, Obesity (Silver Spring), 21 Suppl 1, S1, 10.1002/oby.20461 Gadde, 2018, Obesity: Pathophysiology and management, J Am Coll Cardiol, 71, 69, 10.1016/j.jacc.2017.11.011 Schauer, 2016, Clinical outcomes of metabolic surgery: Efficacy of glycemic control weight loss, and remission of diabetes, Diabetes Care, 39, 902, 10.2337/dc16-0382 Toh, 2009, Prevalence of nutrient deficiencies in bariatric patients, Nutrition, 25, 1050, 10.1016/j.nut.2009.03.012 Parrott, 2017, American Society for metabolic and bariatric surgery integrated health nutritional guidelines for the surgical weight loss patient 2016 update: Micronutrients, Surg Obes Relat Dis, 13, 727, 10.1016/j.soard.2016.12.018 Cohen, 2016, Innovative metabolic operations, Surg Obes Relat Dis, 12, 1247, 10.1016/j.soard.2016.02.034 Schouten, 2010, A multicenter, randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery, Ann Surg, 251, 236, 10.1097/SLA.0b013e3181bdfbff Miras, 2014, Can medical therapy mimic the clinical efficacy of physiological effects of bariatric surgery?, Inter J Obes, 38, 325, 10.1038/ijo.2013.205 Standford, 2017, The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study, Surg Obes Relat Dis, 13, 491, 10.1016/j.soard.2016.10.018 Dixon, 2008, Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial, JAMA, 299, 316, 10.1001/jama.299.3.316 Schauer, 2012, Bariatric surgery versus intensive medical therapy in obese patients, with diabetes, N Eng J Med, 366, 1567, 10.1056/NEJMoa1200225 Schauer, 2014, Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes, N Eng J Med, 370, 2002, 10.1056/NEJMoa1401329 Liang, 2013, Effect of laparoscopic Roux-en Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: A randomized controlled trial, Diabetes Res Clin Pract, 101, 50, 10.1016/j.diabres.2013.04.005 Mingrone, 2012, Bariatric surgery versus conventional medical therapy for type 2 diabetes, N Engl J Med, 366, 1577, 10.1056/NEJMoa1200111 Halperin, 2014, Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: Feasibility and 1-year results of a randomized clinical trial, JAMA Surg, 149, 716, 10.1001/jamasurg.2014.514 Courcoulas, 2014, Surgical vs medical treatments for type 2 diabetes mellitus: A randomized clinical trial, JAMA Surg, 149, 707, 10.1001/jamasurg.2014.467 Courcoulas, 2015, Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: A randomized clinical trial, JAMA Surg, 150, 931, 10.1001/jamasurg.2015.1534 Ding, 2015, Adjustable gastric band surgery or medical management in patients with type 2 diabetes: A randomized clinical trial, J Clin Endocrinol Metab, 100, 2546, 10.1210/jc.2015-1443 Ikramuddin, 2013, Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The Diabetes Surgery Study randomized clinical trial, JAMA, 309, 2240, 10.1001/jama.2013.5835 Ikramuddin, 2015, Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial, Lancet Diabetes Endocrinol, 3, 413, 10.1016/S2213-8587(15)00089-3 Petry, 2015, Effect of duodenal-jejunal bypass surgery on glycemic control in type 2 diabetes: A randomized controlled trial, Obesity (Silver Spring), 23, 1973, 10.1002/oby.21190 Cummings, 2016, Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: The CROSSROADS randomised controlled trial, Diabetologia, 59, 945, 10.1007/s00125-016-3903-x